A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.
A Full Face, Baseline Controlled Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Conjunction with MG-CLR Serum for Acne Treatment Over 12 Weeks.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Stene Marshal
- Phone Number: (949) 798 6207
- Email: stene@dermapenworld.com
Study Contact Backup
- Name: Aahan Sachdev
- Phone Number: 9880755883
- Email: aahan.sachdev@msclinical.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Skin Wellness Dermatology
-
Contact:
- Jordan Rubin
- Phone Number: 205.678.7518
- Email: jrubin@skinwellness.com
-
Contact:
- COREY LOUIS HARTMAN
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female subjects aged between 18-45 years (both ages inclusive)
- Fitzpatrick skin phototype I to VI.
- Subjects having IGA score of 2 and 3.
- Subjects who have not received any kind of treatment for acne 1 month before the start of the study.
- Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face.
- Subjects who agree not to use any other product/treatment/home remedy/ except the provided products on their face during the study period
Exclusion Criteria:
- Subjects with known skin condition that may impact the assessment.
- Subjects with active Herpes labialis infection.
- Subjects known to have bleeding and clotting disorders (self-declared).
- Subjects known to have connective tissue disorders.
- Subjects with any other signs of significant local irritation or skin disease.
- Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: A single arm, full face clinical study.
Dermapen 4 in conjunction with MG-CLR serum
|
Dermapen 4™ conjunction with MG-CLR
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acne severity
Time Frame: 13 weeks
|
Change in acne severity using the modified GAGS scale at all time points when compared to baseline.
|
13 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SKIN/EMAC/2024-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.